{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T19:54:53Z","timestamp":1792958093860,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2017TATYMP_002"],"award-info":[{"award-number":["2017TATYMP_002"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN2017"],"award-info":[{"award-number":["PRIN2017"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001698","name":"Israel Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004740","name":"Fondazione del Monte di Bologna e Ravenna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004740","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ama121054"],"award-info":[{"award-number":["JP22ama121054"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.xcrm.2023.101142","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T11:22:55Z","timestamp":1691493775000},"page":"101142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab"],"prefix":"10.1016","volume":"4","author":[{"given":"Ilaria","family":"Marrocco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvendu","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Simoni-Nieves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rudnitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Haga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Romaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunachalam","family":"Sekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirie","family":"Zerbib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshit","family":"Lindzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon","family":"Fard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Lauriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Tamagnone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4168-7884","authenticated-orcid":false,"given":"Yosef","family":"Yarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2023.101142_bib1","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2013.49.4799","article-title":"Precision oncology: an overview","volume":"31","author":"Garraway","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101142_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2023.101142_bib3","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.xcrm.2023.101142_bib4","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.101142_bib5","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1158\/1078-0432.CCR-10-2571","article-title":"New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101142_bib6","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Gazdar","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2023.101142_bib7","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2023.101142_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2023.101142_bib9","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1200\/JCO.2014.58.1736","article-title":"Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis","volume":"33","author":"Lee","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101142_bib10","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.cell.2006.05.013","article-title":"An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor","volume":"125","author":"Zhang","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2023.101142_bib11","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1021\/bi00379a034","article-title":"Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation","volume":"26","author":"Yarden","year":"1987","journal-title":"Biochemistry"},{"key":"10.1016\/j.xcrm.2023.101142_bib12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/prot.22353","article-title":"Conformational dynamics of the EGFR kinase domain reveals structural features involved in activation","volume":"76","author":"Papakyriakou","year":"2009","journal-title":"Proteins"},{"key":"10.1016\/j.xcrm.2023.101142_bib13","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1158\/0008-5472.CAN-13-1145","article-title":"Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization","volume":"73","author":"Cho","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101142_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.101142_bib15","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-14-0326","article-title":"Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations","volume":"4","author":"Janjigian","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.101142_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2013.11.006","article-title":"Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer","volume":"83","author":"Pujol","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.xcrm.2023.101142_bib17","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/jnci\/dji238","article-title":"Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations","volume":"97","author":"Mukohara","year":"2005","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.xcrm.2023.101142_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1158\/0008-5472.226.65.1","article-title":"Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer","volume":"65","author":"Amann","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101142_bib19","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1073\/pnas.1220763110","article-title":"Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR","volume":"110","author":"Ferraro","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2023.101142_bib20","doi-asserted-by":"crossref","first-page":"e13144","DOI":"10.15252\/emmm.202013144","article-title":"Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models","volume":"13","author":"Marrocco","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.xcrm.2023.101142_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","article-title":"Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy","volume":"20","author":"Du","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2023.101142_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41591-018-0264-7","article-title":"Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer","volume":"25","author":"Shah","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2023.101142_bib23","doi-asserted-by":"crossref","first-page":"59245","DOI":"10.18632\/oncotarget.11043","article-title":"FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET\/AKT-dependent positive feedback loop","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2023.101142_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.semcancer.2017.11.018","article-title":"The FOXO3-FOXM1 axis: a key cancer drug target and a modulator of cancer drug resistance","volume":"50","author":"Yao","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.xcrm.2023.101142_bib25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/2159-8290.CD-11-0106","article-title":"BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors","volume":"1","author":"Faber","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.101142_bib26","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.molcel.2017.10.001","article-title":"Genetically encoded tools for optical dissection of the mammalian cell cycle","volume":"68","author":"Sakaue-Sawano","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2023.101142_bib27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s12859-021-04344-9","article-title":"CellProfiler 4: improvements in speed, utility and usability","volume":"22","author":"Stirling","year":"2021","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.xcrm.2023.101142_bib28","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1158\/1078-0432.CCR-18-0450","article-title":"A combination of approved antibodies overcomes resistance of lung cancer to osimertinib by blocking bypass pathways","volume":"24","author":"Romaniello","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101142_bib29","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.3390\/cancers12092394","article-title":"Targeting HER3, a catalytically defective receptor tyrosine kinase, prevents resistance of lung cancer to a third-generation egfr kinase inhibitor","volume":"12","author":"Romaniello","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2023.101142_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.101142_bib31","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2023.101142_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","article-title":"AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells","volume":"10","author":"Taniguchi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2023.101142_bib33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1083\/jcb.200401142","article-title":"Human chromokinesin KIF4A functions in chromosome condensation and segregation","volume":"166","author":"Mazumdar","year":"2004","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.xcrm.2023.101142_bib34","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.ccell.2021.07.006","article-title":"Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis","volume":"39","author":"Tanaka","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.101142_bib35","first-page":"1169","article-title":"ZD1839 (IRESSA) stabilizes p27Kip1 and enhances radiosensitivity in cholangiocarcinoma cell lines","volume":"29","author":"Yabuuchi","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.xcrm.2023.101142_bib36","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","article-title":"Circumventing cancer drug resistance in the era of personalized medicine","volume":"2","author":"Garraway","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.101142_bib37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2023.101142_bib38","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.1007\/s00253-016-7648-8","article-title":"Persisters-as elusive as ever","volume":"100","author":"Kaldalu","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.xcrm.2023.101142_bib39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.tips.2018.12.004","article-title":"Targeting cancer cell dormancy","volume":"40","author":"Recasens","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.xcrm.2023.101142_bib40","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1126\/science.aav4474","article-title":"Adaptive mutability of colorectal cancers in response to targeted therapies","volume":"366","author":"Russo","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2023.101142_bib41","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/2159-8290.CD-22-0111","article-title":"AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer","volume":"12","author":"Noronha","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2023.101142_bib42","doi-asserted-by":"crossref","first-page":"603640","DOI":"10.3389\/fimmu.2020.603640","article-title":"3D tumor models and their use for the testing of immunotherapies","volume":"11","author":"Boucherit","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2023.101142_bib43","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1158\/0008-5472.CAN-13-1069","article-title":"Patient-derived tumor xenografts: transforming clinical samples into mouse models","volume":"73","author":"Siolas","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101142_bib44","doi-asserted-by":"crossref","first-page":"12105","DOI":"10.1038\/ncomms12105","article-title":"A neomorphic cancer cell-specific role of MAGE-A4 in trans-lesion synthesis","volume":"7","author":"Gao","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2023.101142_bib45","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1126\/science.1120615","article-title":"Ubiquitin-binding domains in Y-family polymerases regulate translesion synthesis","volume":"310","author":"Bienko","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2023.101142_bib46","doi-asserted-by":"crossref","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.xcrm.2023.101142_bib47","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221125706","article-title":"First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis","volume":"13","author":"Chen","year":"2022","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.xcrm.2023.101142_bib48","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ccell.2018.03.025","article-title":"A convergence-based framework for cancer drug resistance","volume":"33","author":"Konieczkowski","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2023.101142_bib49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4939-8958-4_2","article-title":"Cancer immunotherapy: the dawn of antibody cocktails","volume":"1904","author":"Marrocco","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2023.101142_bib50","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/bjc.1987.104","article-title":"Epidermal growth factor receptors in non-small cell lung cancer","volume":"55","author":"Veale","year":"1987","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2023.101142_bib51","first-page":"1002","article-title":"Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies","volume":"44","author":"Masui","year":"1984","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101142_bib52","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2000.18.4.904","article-title":"Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin","volume":"18","author":"Baselga","year":"2000","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101142_bib53","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.101142_bib54","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2023.101142_bib55","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1158\/1078-0432.CCR-20-2748","article-title":"Amphiregulin expression is a predictive biomarker for EGFR inhibition in metastatic colorectal cancer: combined analysis of three randomized trials","volume":"26","author":"Stahler","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2023.101142_bib56","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.20.01149","article-title":"Randomized trial of afatinib plus cetuximab versus afatinib alone for first-line treatment of EGFR-mutant non-small-cell lung cancer: final results from SWOG S1403","volume":"38","author":"Goldberg","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2023.101142_bib57","doi-asserted-by":"crossref","first-page":"14768","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2023.101142_bib58","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s43018-020-0106-7","article-title":"Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors","volume":"1","author":"Keshet","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2023.101142_bib59","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1126\/science.aau8768","article-title":"MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer","volume":"368","author":"Cipponi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2023.101142_bib60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmpb.2014.12.003","article-title":"Cancer multicellular spheroids: volume assessment from a single 2D projection","volume":"118","author":"Piccinini","year":"2015","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.xcrm.2023.101142_bib61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cmpb.2016.07.024","article-title":"Single-image based methods used for non-invasive volume estimation of cancer spheroids: a practical assessing approach based on entry-level equipment","volume":"135","author":"Piccinini","year":"2016","journal-title":"Comput. Methods Programs Biomed."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123002951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379123002951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:57:30Z","timestamp":1762988250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379123002951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2666379123002951"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101142","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2023.101142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"101142"}}